New stock news | Borui Biotechnology Hong Kong IPO prospectus invalidated

Zhejiang Borui Biopharmaceutical Co., Ltd. (referred to as Borui Biopharmaceutical) submitted a Hong Kong stock prospectus on January 6, 2026, which expired after 6 months on July 6, 2026. Huatai International and J.P. Morgan were joint sponsors at the time of submission. Borui Biopharmaceutical is a leading integrated biopharmaceutical company in China, dedicated to providing comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, tumor immunological diseases, and malignant tumors of the immune system itself. According to Frost & Sullivan data, in terms of revenue from biologics for autoimmune diseases, Borui Biopharmaceutical has ranked first among Chinese pharmaceutical companies for two consecutive years since 2023.